search
Back to results

Immediate ART in Subjects With Opportunistic Diseases

Primary Purpose

HIV/AIDS, ANTIRETROVIRAL TREATMENT

Status
Recruiting
Phase
Not Applicable
Locations
Mexico
Study Type
Interventional
Intervention
iART
cART
Sponsored by
Gustavo Reyes-Teran
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for HIV/AIDS focused on measuring HIV/AIDS, ART

Eligibility Criteria

18 Years - 60 Years (Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  • Over 18 years old
  • Time from admission to study entry: less than 48 hours
  • Confirmed HIV diagnosis or high probability of HIV infection based on a positive HIV rapid test
  • Having an opportunistic disease
  • Subjects must be naïve to ART or have failed their first or second ART regimen or must have abandoned ART for more than 3 months

Exclusion Criteria:

  • Meningitis due to Cryptococcus spp. or for M. tuberculosis
  • Pregnancy

Sites / Locations

  • Centro de Investigacion en Enfermedades InfecciosasRecruiting

Arms of the Study

Arm 1

Arm 2

Arm Type

Experimental

Active Comparator

Arm Label

Group A Immediate treatment (iART)

Group B Conventional treatment (cART)

Arm Description

Other: time to start the ART within 48 hours of admission to hospitalization

Other: time to start the ART, after the opportunistic disease has been controlled, at the discretion of infectious disease specialist.

Outcomes

Primary Outcome Measures

Mortality
Compare mortality rates betweeno two groups according to the timing of ART initiation: immediate antiretroviral therapy (iART) versus conventional antiretroviral therapy (cART)

Secondary Outcome Measures

Assess survival rates
Compare the survival rate of HIV-infected patients on immediate antiretroviral therapy (iART) versus conventional antiretroviral therapy (cART)
Assess survival rates
Compare the survival rate of HIV-infected patients on immediate antiretroviral therapy (iART) versus conventional antiretroviral therapy (cART)
Assess survival rates
Compare the survival rate of HIV-infected patients on immediate antiretroviral therapy (iART) versus conventional antiretroviral therapy (cART)
Length of stay
Compare length of hospitalization between both groups
Asses survival rates by the CD4 count
Compare the survival rate of HIV-infected patients on immediate antiretroviral therapy (iART) versus conventional antiretroviral therapy (cART) stratified by CD4+ T cell count at study entry
Asses survival rates by the CD4 count
Compare the survival rate of HIV-infected patients on immediate antiretroviral therapy (iART) versus conventional antiretroviral therapy (cART) stratified by CD4+ T cell count at study entry
Asses survival rates by the CD4 count
Compare the survival rate of HIV-infected patients on immediate antiretroviral therapy (iART) versus conventional antiretroviral therapy (cART) stratified by CD4+ T cell count at study entry
Viral load
Measure the baseline plasma viral load and evaluate its dynamics after ART initiation in both groups
Viral load
Measure the baseline plasma viral load and evaluate its dynamics after ART initiation in both groups
Viral load
Measure the baseline plasma viral load and evaluate its dynamics after ART initiation in both groups
CD4 T cell counts
Measure CD4+ T cell counts, and evaluate its dynamics after ART initiation in both groups
CD4 T cell counts
Measure CD4+ T cell counts, and evaluate its dynamics after ART initiation in both groups
CD4 T cell counts
Measure CD4+ T cell counts, and evaluate its dynamics after ART initiation in both groups
IRIS
Determine the incidence and severity of IRIS. Severity will be classified as mild or life threatening
Adverse reactions
Describe ART-related adverse events, and drug interactions

Full Information

First Posted
January 18, 2019
Last Updated
February 15, 2022
Sponsor
Gustavo Reyes-Teran
search

1. Study Identification

Unique Protocol Identification Number
NCT03825523
Brief Title
Immediate ART in Subjects With Opportunistic Diseases
Official Title
Impact of the Timing of Antiretroviral Therapy Initiation (Immediate Versus Early) on the Mortality Rate of HIV/AIDS Patients Hospitalized With an Opportunistic Disease
Study Type
Interventional

2. Study Status

Record Verification Date
February 2022
Overall Recruitment Status
Recruiting
Study Start Date
February 18, 2019 (Actual)
Primary Completion Date
December 2023 (Anticipated)
Study Completion Date
December 2024 (Anticipated)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor-Investigator
Name of the Sponsor
Gustavo Reyes-Teran

4. Oversight

Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
Yes

5. Study Description

Brief Summary
The aim of this study is to compare the clinical response and mortality rate by an opportunistic disease in HIV-infected individuals who start immediate versus conventional antiretroviral therapy. Immediate ART (iART) is defined as starting antiretroviral therapy in the first 48 hours after the hospitalization. Conventional ART (cART) is defined as starting antiretroviral therapy once the opportunistic infection is under control at the discretion of infectious disease specialist.
Detailed Description
Sample size was calculated using formula, of difference in proportions formula using a beta of 0.1, alpha of 0.05 and an expected difference in mortality of 20%, The sample size is 225 subjects in each group. Informed consent will be obtained. Patients will be allocated to each group (iART or cART) after randomization stratified by the CD4+ T cell count (less or more than 50 cells/mm3). Plasma viral load and CD4+ T cell count will be measured at study entry and at weeks 2, 4, 12, 24 and 48 after ART initiation. Clinical outcomes will be: mortality at 4, 12, 24, and 48 weeks, length of hospitalization (measured in days), clinical and microbiological cure of the opportunistic disease, incidence and severity of immune reconstitution of inflammatory syndrome (IRIS), and adverse drug reactions and interactions. Once 50% of the sample size has completed 30 days of follow-up, a preliminary analysis will be conducted to assess safety and efficacy of iART; if differences in the mortality are observed, the study will be terminated.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
HIV/AIDS, ANTIRETROVIRAL TREATMENT
Keywords
HIV/AIDS, ART

7. Study Design

Primary Purpose
Treatment
Study Phase
Not Applicable
Interventional Study Model
Parallel Assignment
Model Description
Stratified randomization will be generated by an electronic system, in blocks of 6 and 8, and a 1:1 ratio, according to the CD4+ T cell count. Group A: Immediate treatment (iART). Start ART within 48 hours of admission and hospitalization; Group B: Conventional treatment (cART). Start the ART once the opportunistic infection is under control at the discretion of infectious disease specialist.
Masking
None (Open Label)
Allocation
Randomized
Enrollment
448 (Anticipated)

8. Arms, Groups, and Interventions

Arm Title
Group A Immediate treatment (iART)
Arm Type
Experimental
Arm Description
Other: time to start the ART within 48 hours of admission to hospitalization
Arm Title
Group B Conventional treatment (cART)
Arm Type
Active Comparator
Arm Description
Other: time to start the ART, after the opportunistic disease has been controlled, at the discretion of infectious disease specialist.
Intervention Type
Other
Intervention Name(s)
iART
Intervention Description
After group assignment, ART will be started within the first 48 hours after admission to the hospital. ART regimen will be decided according to each subject´s the clinical characteristics
Intervention Type
Other
Intervention Name(s)
cART
Intervention Description
After group assignment, ART is started at the discretion of the attending physician. ART regimen will be decided according to each subject´s the clinical characteristics
Primary Outcome Measure Information:
Title
Mortality
Description
Compare mortality rates betweeno two groups according to the timing of ART initiation: immediate antiretroviral therapy (iART) versus conventional antiretroviral therapy (cART)
Time Frame
30 days
Secondary Outcome Measure Information:
Title
Assess survival rates
Description
Compare the survival rate of HIV-infected patients on immediate antiretroviral therapy (iART) versus conventional antiretroviral therapy (cART)
Time Frame
90 days since starting antiretroviral therapy (ART)
Title
Assess survival rates
Description
Compare the survival rate of HIV-infected patients on immediate antiretroviral therapy (iART) versus conventional antiretroviral therapy (cART)
Time Frame
180 days since starting antiretroviral therapy (ART)
Title
Assess survival rates
Description
Compare the survival rate of HIV-infected patients on immediate antiretroviral therapy (iART) versus conventional antiretroviral therapy (cART)
Time Frame
360 days since starting antiretroviral therapy (ART)
Title
Length of stay
Description
Compare length of hospitalization between both groups
Time Frame
1 year
Title
Asses survival rates by the CD4 count
Description
Compare the survival rate of HIV-infected patients on immediate antiretroviral therapy (iART) versus conventional antiretroviral therapy (cART) stratified by CD4+ T cell count at study entry
Time Frame
90 days
Title
Asses survival rates by the CD4 count
Description
Compare the survival rate of HIV-infected patients on immediate antiretroviral therapy (iART) versus conventional antiretroviral therapy (cART) stratified by CD4+ T cell count at study entry
Time Frame
180 days
Title
Asses survival rates by the CD4 count
Description
Compare the survival rate of HIV-infected patients on immediate antiretroviral therapy (iART) versus conventional antiretroviral therapy (cART) stratified by CD4+ T cell count at study entry
Time Frame
360 days
Title
Viral load
Description
Measure the baseline plasma viral load and evaluate its dynamics after ART initiation in both groups
Time Frame
90 days
Title
Viral load
Description
Measure the baseline plasma viral load and evaluate its dynamics after ART initiation in both groups
Time Frame
180 days
Title
Viral load
Description
Measure the baseline plasma viral load and evaluate its dynamics after ART initiation in both groups
Time Frame
360 days
Title
CD4 T cell counts
Description
Measure CD4+ T cell counts, and evaluate its dynamics after ART initiation in both groups
Time Frame
90 days
Title
CD4 T cell counts
Description
Measure CD4+ T cell counts, and evaluate its dynamics after ART initiation in both groups
Time Frame
180 days
Title
CD4 T cell counts
Description
Measure CD4+ T cell counts, and evaluate its dynamics after ART initiation in both groups
Time Frame
360 days
Title
IRIS
Description
Determine the incidence and severity of IRIS. Severity will be classified as mild or life threatening
Time Frame
48 weeks
Title
Adverse reactions
Description
Describe ART-related adverse events, and drug interactions
Time Frame
48 weeks

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
60 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Over 18 years old Time from admission to study entry: less than 48 hours Confirmed HIV diagnosis or high probability of HIV infection based on a positive HIV rapid test Having an opportunistic disease Subjects must be naïve to ART or have failed their first or second ART regimen or must have abandoned ART for more than 3 months Exclusion Criteria: Meningitis due to Cryptococcus spp. or for M. tuberculosis Pregnancy
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
GUSTAVO MD REYES-TERÁN, M.D.
Phone
56667985
Ext
100
Email
gustavo.reyesteran@gmail.com
First Name & Middle Initial & Last Name or Official Title & Degree
Amy MD Peralta, M.D.
Phone
56667985
Ext
100
Email
amy.peralta@cieni.org.mx
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
GUSTAVO MD REYES-TERÁN, M.D.
Organizational Affiliation
Instituto Nacional de Enfermedades Respiratorias
Official's Role
Principal Investigator
Facility Information:
Facility Name
Centro de Investigacion en Enfermedades Infecciosas
City
Mexico
ZIP/Postal Code
14080
Country
Mexico
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Gustavo Reyes-Teran, M.D.
Phone
+52(55)56667985
First Name & Middle Initial & Last Name & Degree
Yuria Ablanedo-Terrazas, M.D.
Phone
+52(55)56667985
First Name & Middle Initial & Last Name & Degree
Gustavo Reyes-Teran, M.D.
First Name & Middle Initial & Last Name & Degree
Amy Bethel Peralta Prado, M.D.

12. IPD Sharing Statement

Learn more about this trial

Immediate ART in Subjects With Opportunistic Diseases

We'll reach out to this number within 24 hrs